• Jobs
  • Startups
  • Hire
LoginSign up

Umoja Biopharma

Umoja Biopharma has 8 open roles, 3 posted in the last 30 days. Stated pay range: $125k – $394k a year.

Open roles

  • Umoja Biopharma logo
    Director, Program Management

    Umoja Biopharma

    • Seattle, WA
    • Hybrid · Director / Executive
    • $207k–$309k
    umoja-biopharma.com
    Posted 18d ago
  • Umoja Biopharma logo
    Senior Program Manager (Contract)

    Umoja Biopharma

    • Seattle, WA
    • Senior
    • $66.83–$82.79/hr
    umoja-biopharma.com
    Posted 23d ago
  • Umoja Biopharma logo
    Senior Manager, Manufacturing

    Umoja Biopharma

    • Louisville, CO
    • On-site · Senior
    • $125k–$182k
    umoja-biopharma.com
    Posted 24d ago
  • Umoja Biopharma logo
    Vice President, Head of Portfolio & Program Strategy

    Umoja Biopharma

    • Seattle, WA
    • Hybrid · Director / Executive
    • $293k–$362k
    umoja-biopharma.com
    Posted 32d ago
  • Umoja Biopharma logo
    Senior Clinical & Statistical Programmer

    Umoja Biopharma

    • Seattle, WA
    • Remote · Senior
    • $153k–$189k
    umoja-biopharma.com
    Posted 36d ago
  • Umoja Biopharma logo
    Senior Manager, Clinical Regulatory Affairs

    Umoja Biopharma

    • Seattle, WA
    • Remote · Senior
    • $160k–$203k
    umoja-biopharma.com
    Posted 59d ago
Show all roles

About

Umoja Biopharma logo

Umoja Biopharma

Next Generation Immunotherapies

Umoja is developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer. We envision a world where all patients have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.

Private companyIn the news
Founded2019
HQSeattle, United States
Size51–200 employees
Unlock human wisdom
ThesisTermsPrivacy
Industry
Biotechnology Research
News
  • Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting
  • Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting

Claim umoja-biopharma.com

Work at umoja-biopharma.com? Sign in to claim this org and manage its profile.

© 2026 Saywise Inc.